SENTINEL U READINESS
ESSENTIALS IVY JACKSON |
COMPLETE QUESTIONS &
LATEST MOCK PRACTICE SET
150 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
SENTINEL U READINESS ESSENTIALS IVY JACKSON | COMPLETE QUESTIONS & ANSWERS | MAJOR
DEPRESSIVE DISORDER (MDD) CASE STUDY | 2026 UPDATE | 100% CORRECT.. It contains 150 carefully
selected questions that reflect the most current exam content and testing strategies. Each question is
accompanied by a correct answer and a detailed rationale that explains the underlying pathophysiology,
pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 150 Questions
Foundations - Application - Sentinel U Readiness Essentials IVY Jackson Complete & Major Depressive
Disorder MDD CASE Study 2026 Update 100 Correct Psychiatric Mental Health Nursing / Advanced Clinical
Reasoning Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Major Depressive Disorder 1-25 Disorder, Depression, Strongly, Antidepressant, Strategy
Clinical Presentation AND
Diagnostic Criteria
RISK Factors AND Etiology 26-50 IVY Jackson S, MDD CASE, Sertraline, Treatment-resistant,
OF Major Depressive Depression
Disorder
Assessment AND Screening 51-75 Weeks, IVY Jackson, Appropriate, Treatment, Sertraline
Tools FOR MDD
Pharmacological 76-100 IVY S, Sertraline, Reports, Depression, Phq-9
Interventions
Antidepressants AND
Management
Psychotherapeutic 101-125 Treatment, Evidence, Current, Antidepressant, Finding
Approaches CBT
Interpersonal Therapy AND
Others
Safety Planning AND Suicide 126-150 Depression, Treatment, Critical, Fluoxetine, Clinical
RISK Assessment
TOTAL 150 All questions include answers and detailed rationales
,Section A - Major Depressive Disorder Clinical
Presentation AND Diagnostic Criteria
Q1.
In a patient with treatment-resistant depression who has failed two adequate trials of
SSRIs, which augmentation strategy is most strongly supported by recent evidence for
rapid symptom improvement?
A. Adding a second SSRI B. Adding low-dose aripiprazole
C. Adding omega-3 fatty acids D. Adding buspirone
Correct: B - Adding low-dose aripiprazole
Rationale:Aripiprazole is FDA-approved as an adjunct for MDD and has robust evidence for
efficacy in treatment-resistant depression. Combining two SSRIs lacks evidence and
increases side effects. Omega-3 and buspirone have weaker or inconsistent evidence.
Q2.
Which neurobiological finding is most specifically associated with melancholic features of
MDD and supports the use of electroconvulsive therapy (ECT) as a first-line treatment?
A. Hyperactivity of the B. Reduced hippocampal volume due to
hypothalamic-pituitary-adrenal axis with chronic stress
elevated cortisol
C. Decreased serotonin transporter binding D. Increased inflammatory cytokines in
in the raphe nuclei peripheral blood
Correct: A - Hyperactivity of the hypothalamic-pituitary-adrenal axis with elevated cortisol
Rationale:Melancholic depression is characterized by hypercortisolemia and HPA axis
dysregulation, and ECT is particularly effective in this subtype. Hippocampal atrophy and
inflammation are not specific to melancholia. Serotonin transporter changes are seen across
MDD but not specific.
Q3.
A patient on fluoxetine for 8 weeks reports significant improvement but now experiences
persistent insomnia and sexual dysfunction. Which pharmacogenetic consideration is
most relevant to this adverse effect profile?
A. CYP2D6 poor metabolizer status B. CYP2C19 ultra-rapid metabolizer status
C. SLC6A4 5-HTTLPR short allele D. HTR2A receptor polymorphism
Correct: A - CYP2D6 poor metabolizer status
Page 3
, Section A - Major Depressive Disorder Clinical Presentation AND Diagnostic Criteria
Rationale: Fluoxetine is a strong CYP2D6 inhibitor and substrate; poor metabolizers
accumulate higher levels, increasing side effects like insomnia and sexual dysfunction.
CYP2C19 is more relevant to escitalopram/sertraline. 5-HTTLPR and HTR2A affect efficacy,
not primarily side effects.
Q4.
Which intervention is most appropriate as a first-line response to a patient with MDD who
expresses passive suicidal ideation but has no plan or intent and shows protective
factors?
A. Immediate inpatient psychiatric B. Intensive outpatient program with safety
hospitalization planning
C. Emergency department evaluation for D. Discharge with a follow-up phone call in
involuntary hold 48 hours
Correct: B - Intensive outpatient program with safety planning
Rationale:Passive SI without plan/intent and with protective factors can be managed in an
intensive outpatient setting with a safety plan. Inpatient is reserved for high risk. ED hold is
not indicated. Discharge without structured follow-up is unsafe.
Q5.
Which mechanism of action best explains the rapid antidepressant effect of intravenous
ketamine in treatment-resistant depression?
A. NMDA receptor antagonism leading to B. Monoamine oxidase inhibition increasing
increased AMPA-to-NMDA throughput and synaptic serotonin and norepinephrine
synaptogenesis
C. Selective serotonin reuptake inhibition D. Dopamine D2 receptor blockade altering
enhancing serotonergic transmission over mesolimbic reward pathways
weeks
Correct: A - NMDA receptor antagonism leading to increased AMPA-to-NMDA throughput
and synaptogenesis
Rationale:Ketamine blocks NMDA receptors, increasing AMPA receptor activity and
triggering synaptogenesis, producing effects within hours. MAOIs and SSRIs take weeks. D2
blockade is for antipsychotics, not depression.
Q6.
A patient with MDD and comorbid generalized anxiety disorder is started on sertraline.
After 4 weeks, anxiety has worsened. Which strategy is most evidence-based to manage
this initial exacerbation?
Page 4
ESSENTIALS IVY JACKSON |
COMPLETE QUESTIONS &
LATEST MOCK PRACTICE SET
150 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
SENTINEL U READINESS ESSENTIALS IVY JACKSON | COMPLETE QUESTIONS & ANSWERS | MAJOR
DEPRESSIVE DISORDER (MDD) CASE STUDY | 2026 UPDATE | 100% CORRECT.. It contains 150 carefully
selected questions that reflect the most current exam content and testing strategies. Each question is
accompanied by a correct answer and a detailed rationale that explains the underlying pathophysiology,
pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 150 Questions
Foundations - Application - Sentinel U Readiness Essentials IVY Jackson Complete & Major Depressive
Disorder MDD CASE Study 2026 Update 100 Correct Psychiatric Mental Health Nursing / Advanced Clinical
Reasoning Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Major Depressive Disorder 1-25 Disorder, Depression, Strongly, Antidepressant, Strategy
Clinical Presentation AND
Diagnostic Criteria
RISK Factors AND Etiology 26-50 IVY Jackson S, MDD CASE, Sertraline, Treatment-resistant,
OF Major Depressive Depression
Disorder
Assessment AND Screening 51-75 Weeks, IVY Jackson, Appropriate, Treatment, Sertraline
Tools FOR MDD
Pharmacological 76-100 IVY S, Sertraline, Reports, Depression, Phq-9
Interventions
Antidepressants AND
Management
Psychotherapeutic 101-125 Treatment, Evidence, Current, Antidepressant, Finding
Approaches CBT
Interpersonal Therapy AND
Others
Safety Planning AND Suicide 126-150 Depression, Treatment, Critical, Fluoxetine, Clinical
RISK Assessment
TOTAL 150 All questions include answers and detailed rationales
,Section A - Major Depressive Disorder Clinical
Presentation AND Diagnostic Criteria
Q1.
In a patient with treatment-resistant depression who has failed two adequate trials of
SSRIs, which augmentation strategy is most strongly supported by recent evidence for
rapid symptom improvement?
A. Adding a second SSRI B. Adding low-dose aripiprazole
C. Adding omega-3 fatty acids D. Adding buspirone
Correct: B - Adding low-dose aripiprazole
Rationale:Aripiprazole is FDA-approved as an adjunct for MDD and has robust evidence for
efficacy in treatment-resistant depression. Combining two SSRIs lacks evidence and
increases side effects. Omega-3 and buspirone have weaker or inconsistent evidence.
Q2.
Which neurobiological finding is most specifically associated with melancholic features of
MDD and supports the use of electroconvulsive therapy (ECT) as a first-line treatment?
A. Hyperactivity of the B. Reduced hippocampal volume due to
hypothalamic-pituitary-adrenal axis with chronic stress
elevated cortisol
C. Decreased serotonin transporter binding D. Increased inflammatory cytokines in
in the raphe nuclei peripheral blood
Correct: A - Hyperactivity of the hypothalamic-pituitary-adrenal axis with elevated cortisol
Rationale:Melancholic depression is characterized by hypercortisolemia and HPA axis
dysregulation, and ECT is particularly effective in this subtype. Hippocampal atrophy and
inflammation are not specific to melancholia. Serotonin transporter changes are seen across
MDD but not specific.
Q3.
A patient on fluoxetine for 8 weeks reports significant improvement but now experiences
persistent insomnia and sexual dysfunction. Which pharmacogenetic consideration is
most relevant to this adverse effect profile?
A. CYP2D6 poor metabolizer status B. CYP2C19 ultra-rapid metabolizer status
C. SLC6A4 5-HTTLPR short allele D. HTR2A receptor polymorphism
Correct: A - CYP2D6 poor metabolizer status
Page 3
, Section A - Major Depressive Disorder Clinical Presentation AND Diagnostic Criteria
Rationale: Fluoxetine is a strong CYP2D6 inhibitor and substrate; poor metabolizers
accumulate higher levels, increasing side effects like insomnia and sexual dysfunction.
CYP2C19 is more relevant to escitalopram/sertraline. 5-HTTLPR and HTR2A affect efficacy,
not primarily side effects.
Q4.
Which intervention is most appropriate as a first-line response to a patient with MDD who
expresses passive suicidal ideation but has no plan or intent and shows protective
factors?
A. Immediate inpatient psychiatric B. Intensive outpatient program with safety
hospitalization planning
C. Emergency department evaluation for D. Discharge with a follow-up phone call in
involuntary hold 48 hours
Correct: B - Intensive outpatient program with safety planning
Rationale:Passive SI without plan/intent and with protective factors can be managed in an
intensive outpatient setting with a safety plan. Inpatient is reserved for high risk. ED hold is
not indicated. Discharge without structured follow-up is unsafe.
Q5.
Which mechanism of action best explains the rapid antidepressant effect of intravenous
ketamine in treatment-resistant depression?
A. NMDA receptor antagonism leading to B. Monoamine oxidase inhibition increasing
increased AMPA-to-NMDA throughput and synaptic serotonin and norepinephrine
synaptogenesis
C. Selective serotonin reuptake inhibition D. Dopamine D2 receptor blockade altering
enhancing serotonergic transmission over mesolimbic reward pathways
weeks
Correct: A - NMDA receptor antagonism leading to increased AMPA-to-NMDA throughput
and synaptogenesis
Rationale:Ketamine blocks NMDA receptors, increasing AMPA receptor activity and
triggering synaptogenesis, producing effects within hours. MAOIs and SSRIs take weeks. D2
blockade is for antipsychotics, not depression.
Q6.
A patient with MDD and comorbid generalized anxiety disorder is started on sertraline.
After 4 weeks, anxiety has worsened. Which strategy is most evidence-based to manage
this initial exacerbation?
Page 4
